Discontinuation of dual antiplatelet therapy over 12 months after acute coronary syndromes increases risk for adverse events in patients treated with percutaneous coronary intervention: Systematic review and meta-analysis

Journal of Interventional Cardiology

Volumn 27, Issue 3, 2014, Pages 233-241

  D'Ascenzo, Fabrizio ^a,b   Colombo, Francesco ^a   Barbero, Umberto ^a   Moretti, Claudio ^a,b   Omedè, Pierluigi ^a   Reed, Matthew J ^c   Tarantini, Giuseppe ^d   Frati, Giacomo ^e   Di Nicolantonio, James J ^f   Biondi Zoccai, Giuseppe ^b,e   Gaita, Fiorenzo ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b Meta analysis and Evidence Based Medicine Training in Cardiology (METCARDIO) Wegmans Pharmacy Ithaca   (United States)

^c Department of Emergency Medicine ^*  (United Kingdom)

^d UNIVERSITY OF PADOVA   (Italy)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

^f SAINT LUKE S MID AMERICA HEART INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; ANTITHROMBOCYTIC AGENT;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ARTICLE; COCHRANE LIBRARY; CORONARY RISK; CORONARY STENT; DRUG ELUTING STENT; DRUG WITHDRAWAL; DUAL ANTIPLATELET THERAPY; FOLLOW UP; HUMAN; MEDLINE; META ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK ASSESSMENT; SAPHENOUS VEIN GRAFT; SYSTEMATIC REVIEW; THROMBOCYTE AGGREGATION INHIBITION; TRANSLUMINAL CORONARY ANGIOPLASTY; ADVERSE EFFECTS; AGED; CLASSIFICATION; COMBINATION DRUG THERAPY; CORONARY THROMBOSIS; FEMALE; MALE; ODDS RATIO; PERCUTANEOUS CORONARY INTERVENTION; RISK; STATISTICS AND NUMERICAL DATA; STENT; TIME FACTOR; TREATMENT WITHDRAWAL;

ACUTE CORONARY SYNDROME; AGED; CORONARY THROMBOSIS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; ODDS RATIO; OUTCOME ASSESSMENT (HEALTH CARE); PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; RISK; STENTS; TIME FACTORS; WITHHOLDING TREATMENT;

EID: 84902081480     PISSN: 08964327     EISSN: 15408183     Source Type: Journal    
DOI: 10.1111/joic.12107     Document Type: Article

References (48)

1. Biondi-Zoccai G, Lotrionte M, Agostoni P, et al. Adjusted indirect comparison meta-analysis of prasugrel versus ticagrelor for patients with acute coronary syndromes. Int J Cardiol 2011; 150 (3): 325-331.
2. Biondi-Zoccai G, Abbate A, D'Ascenzo F, et al. Prasugrel during primary percutaneous coronary intervention: Evidence from clinical data. Curr Vasc Pharmacol 2012; 10 (4): 454-457.
3. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502. (Pubitemid 32758501)
4. Wiviott S, Braunwald E, McCabe C, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-2015. (Pubitemid 350106708)
5. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045-1057.
6. Steg PG, James S, Harrington RA, et al. ST-elevation acute coronary syndromes in the Platelet Inhibition and Patient Outcomes (PLATO) trial: Insights from the ECG substudy. Circulation 2012; 125 (3): 514-521.
7. Harrington RA, Califf RM., Late ischemic events after clopidogrel cessation following drug-eluting stenting: Should we be worried ? J Am Coll Cardiol 2006; 48: 2592-2595.
8. Sambu N, Warner T, Curzen N., Clopidogrel withdrawal: Is there a "rebound" phenomenon ? Thromb Haemost 2011; 105: 211-220.
9. Ferrari E, Benhamou M, Cerboni P, et al. Coronary syndromes following aspirin withdrawal: A special risk for late stent thrombosis. J Am Coll Cardiol 2005; 45 (3): 456-459. (Pubitemid 40186800)
10. D'Ascenzo F, Bollati M, Clementi F, et al. Incidence and predictors of coronary stent thrombosis: Evidence from an international collaborative meta-analysis including 30 studies, 221,066 patients, and 4276 thromboses. Int J Cardiol 2013; 167 (2): 575-584.
11. Stone GW, Maehara A, Lansky AJ, et al. A prospective natural-history study of coronary atherosclerosis. N Engl J Med 2011; 364 (3): 226-235.
12. Sanidas EA, Mintz GS, Maehara A, et al. Adverse cardiovascular events arising from atherosclerotic lesions with and without angiographic disease progression. JACC Cardiovasc Imaging 2012; 5 (Suppl. 3): S95-S105.
13. Berger PB., Optimal duration of clopidogrel use after implantation of drug-eluting stents-Still in doubt. N Engl J Med 2010; 362: 1441-1443.
14. Moher D, Cook DJ, Eastwood S, et al. Improving the quality of reports of meta-analyses of randomised controlled trials: The QUOROM statement. Quality of Reporting of Meta-analyses. Lancet 1999; 354: 1896-1900.
15. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: Explanation and elaboration. BMJ 2009; 339: b2700.
16. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: A proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283: 2008-2012. (Pubitemid 30214957)
17. Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. The Cochrane Collaboration, 2009. Available from www.cochrane-handbook.org (last accessed on February 11, 2011).
18. Wilczynski NL, Haynes RB., for the Hedges Team. Developing optimal search strategies for detecting clinically sound prognostic studies in MEDLINE: An analytic survey. BMC Med 2004; 2: 23.
19. Poorhosseini HR, Hosseini SK, Davarpasand T, et al. Effectiveness of Two-Year versus One-Year Use of Dual Antiplatelet Therapy in Reducing the Risk of Very Late Stent Thrombosis after Drug-Eluting Stent Implantation. J Tehran Heart Cent 2012; 7 (2): 47-52.
20. Sachdeva A, Bavisetty S, Beckham G, et al. Discontinuation of long term clopidogrel therapy is associated with death and myocardial infarction after saphenous vein graft percutaneous coronary intervention. J Am Coll Cardiol 2012; 60 (23): 2357-2363.
21. Schulz S, Schuster T, Mehilli J, et al. Stent thrombosis after drug-eluting stent implantation: Incidence, timing, relation to discontinuation of clopidogrel therapy over a 4-year period. Eur Heart J 2009; 30 (22): 2714-2721.
22. Gwon HC, Hahn JY, Park KW, et al. Six-month versus 12 month dual antiplatelet therapy after implantation of drug-eluting stents: The Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study. Circulation 2012; 125 (3): 505-513.
23. Lee SW, Park SW, Kim YH, et al. A randomized, double-blind, multicenter comparison study of triple antiplatelet therapy with dual antiplatelet therapy to reduce restenosis after drug-eluting stent implantation in long coronary lesions: Results from the DECLARE-LONG II (Drug-Eluting Stenting Followed by Cilostazol Treatment Reduces Late Restenosis in Patients with Long Coronary Lesions) trial. J Am Coll Cardiol 2011; 57 (11): 1264-1270.
24. Kovacic JC, Lee P, Karajgikar R, et al. Safety of temporary and permanent suspension of antiplatelet therapy after drug eluting stent implantation in contemporary "real-world" practice. J Interv Cardiol 2012; 25 (5): 482-492.
25. Ferreira-González I, Marsal JR, Ribera A, et al. Double antiplatelet therapy after drug-eluting stent implantation: Risk associated with discontinuation within the first year. J Am Coll Cardiol 2012; 60 (15): 1333-1339.
26. Page RL II, Ghushchyan V, Allen RR, et al. Costs and outcomes associated with clopidogrel discontinuation in Medicare beneficiaries with acute coronary syndrome in the coverage gap. Drug Healthc Patient Saf 2012; 4: 67-74.
27. Ernst FR, Johnston S, Curkendall S, et al. Effect of early clopidogrel discontinuation on rehospitalization in acute coronary syndrome: Results from two distinct patient populations. Am J Health Syst Pharm 2011; 68 (11): 1015-1024.
28. Worthley SG, Abizaid A, Banning A, et al. One year clinical outcomes after sirolimus eluting coronary stent implantation for acute myocardial infarction in the worldwide e-SELECT registry. J Interv Cardiol 2012; 25 (3): 253-261.
29. Charlot M, Nielsen LH, Lindhardsen J, et al. Clopidogrel discontinuation after myocardial infarction, risk of thrombosis: A nationwide cohort study. Eur Heart J 2012; 33 (20): 2527-2534.
30. Ho PM, Peterson ED, Wang L, et al. Incidence of death, acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome. JAMA 2008; 299 (5): 532-539. (Pubitemid 351222546)
31. Stephenson JJ, Chang CL, Devecchis Wygant G, et al. Incidence of death and recurring acute coronary syndrome after stopping clopidogrel therapy in a large commercially-insured population in the US. Curr Med Res Opin 2011; 27 (6): 1079-1087.
32. Boggon R, van Staa TP, Timmis A, et al. Clopidogrel discontinuation after acute coronary syndromes: Frequency, predictors and associations with death and myocardial infarction-A hospital registry-primary care linked cohort (MINAP-GPRD). Eur Heart J 2011; 32 (19): 2376-2386.
33. Valgimigli M, Campo G, Monti M, et al. Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: A randomized multicenter trial. Circulation 2012; 125 (16): 2015-2026.
34. Valgimigli M, Saia F, Guastaroba P, et al. Transradial versus transfemoral intervention for acute myocardial infarction: A propensity score-adjusted and -matched analysis from the REAL (REgistro regionale AngiopLastiche dell'-Emilia-Romagna) multicenter registry. JACC Cardiovasc Interv 2012; 5: 23.
35. Taneja AK, Collinson J, Flather MD, et al. Mortality following non-ST elevation acute coronary syndrome: 4 years follow-up of the PRAIS UK Registry (Prospective Registry of Acute Ischaemic Syndromes in the UK). Eur Heart J 2004; 25 (22): 2013-2028.
36. Holmes DR Jr, Kereiakes DJ, Garg S, et al. Stent thrombosis. J Am Coll Cardiol 2010; 56: 1357-1365.
37. Palmerini T, Biondi-Zoccai G, Della Riva D, et al. Stent thrombosis with drug-eluting and bare-metal stents: Evidence from a comprehensive network meta-analysis. Lancet 2012; 379 (9824): 1393-1402.
38. Sardella G, Mancone M, Biondi-Zoccai G, et al. Beneficial impact of prolonged dual antiplatelet therapy after drug-eluting stent implantation. J Interv Cardiol 2012; 25 (6): 596-603.
39. Eisenstein EL, Anstrom KJ, Kong DF, et al. Clopidogrel use, long-term clinical outcomes after drug-eluting stent implantation. JAMA 2007; 297 (2): 159-168. (Pubitemid 46089732)
40. Faxon DP, Lawler E, Young M, et al. Prolonged clopidogrel use after bare metal and drug-eluting stent placement: The Veterans Administration drug-eluting stent study. Circ Cardiovasc Interv 2012; 5 (3): 372-380.
41. Harjai KJ, Shenoy C, Orshaw P, et al. Dual antiplatelet therapy for more than 12 months after percutaneous coronary intervention: Insights from the Guthrie PTCA Registry. Heart 2009; 95 (19): 1579-1586.
42. Tada T, Natsuaki M, Morimoto T, et al. Duration of dual antiplatelet therapy and long-term clinical outcome after coronary drug-eluting stent implantation: Landmark analyses from the CREDO-Kyoto PTCA/CABG Registry Cohort-2. Circ Cardiovasc Interv 2012; 5 (3): 381-391.
43. Park SJ, Park DW, Kim YH, et al. Duration of dual antiplatelet therapy after implantation of drug-eluting stents. N Engl J Med 2010; 362 (15): 1374-1382.
44. Cassese S, Byrne RA, Tada T, et al. Clinical impact of extended dual antiplatelet therapy after percutaneous coronary interventions in the drug-eluting stent era: A meta-analysis of randomized trials. Eur Heart J 2012; 33 (24): 3078-3087.
45. Bhatt DL, Flather MD, Hacke W, et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol 2007; 49 (19): 1982-1988. Epub 2007 Apr. 11. (Pubitemid 46694290)
46. Berger PB, Bhatt DL, Fuster V, et al. Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: Results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Circulation 2010; 121 (23): 2575-2583.
47. D'Ascenzo F, Biondi-Zoccai G, Moretti C, et al. TIMI, GRACE and alternative risk scores in acute coronary syndromes: A meta-analysis of 40 derivation studies on 216,552 patients and of 42 validation studies on 31,625 patients. Contemp Clin Trials 2012; 33 (3): 507-514.
48. Flores-Ríos X, Couto-Mallõn D, Rodríguez-Garrido J, et al. Comparison of the performance of the CRUSADE, ACUITY-HORIZONS, and ACTION bleeding risk scores in STEMI undergoing primary PCI: Insights from a cohort of 1391 patients. Eur Heart J Acute Cardiovasc Care 2013; 2 (1): 19-26.